HIMS HERS HEALTH INC

NYSE: HIMS (Hims & Hers Health, Inc.)

Last update: 15 Jul, 1:15PM

50.89

-1.14 (-2.19%)

Previous Close 52.03
Open 53.00
Volume 15,544,789
Avg. Volume (3M) 47,019,461
Market Cap 11,390,810,112
Price / Earnings (TTM) 74.84
Price / Earnings (Forward) 96.15
Price / Sales 6.25
Price / Book 20.51
52 Weeks Range
13.47 (-73%) — 72.98 (43%)
Earnings Date 4 Aug 2025
Profit Margin 9.21%
Operating Margin (TTM) 10.12%
Diluted EPS (TTM) 0.680
Quarterly Revenue Growth (YOY) 110.70%
Quarterly Earnings Growth (YOY) 344.70%
Total Debt/Equity (MRQ) 11.54%
Current Ratio (MRQ) 1.59
Operating Cash Flow (TTM) 334.34 M
Levered Free Cash Flow (TTM) 213.45 M
Return on Assets (TTM) 10.76%
Return on Equity (TTM) 36.79%

Market Trend

Short Term Medium Term
Industry Household & Personal Products (US) Bearish Bearish
Household & Personal Products (Global) Bearish Bearish
Stock Hims & Hers Health, Inc. Bullish Bullish

AIStockmoo Score

-0.2
Analyst Consensus -1.5
Insider Activity -3.5
Price Volatility -0.5
Technical Moving Averages 5.0
Technical Oscillators -0.5
Average -0.20

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
HIMS 11 B - 74.84 20.51
ELF 7 B - 61.27 8.94
PG 360 B 1.31% 23.58 7.02
UL 150 B 2.33% 23.39 7.23
CL 75 B 1.08% 26.28 97.50
KMB 45 B 3.64% 18.63 35.54

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.

Sector Consumer Defensive
Industry Household & Personal Products
Investment Style Small Growth
% Held by Insiders 11.13%
% Held by Institutions 82.47%

Ownership

Name Date Shares Held
Yong Rong (Hk) Asset Management Ltd 31 Mar 2025 2,400,000
52 Weeks Range
13.47 (-73%) — 72.98 (43%)
Price Target Range
40.00 (-21%) — 65.00 (27%)
High 65.00 (Needham, 27.73%) Buy
Median 48.00 (-5.68%)
Low 40.00 (Morgan Stanley, -21.40%) Hold
Average 51.00 (0.22%)
Total 1 Buy, 2 Hold
Avg. Price @ Call 53.72
Firm Date Target Price Call Price @ Call
Truist Securities 17 Jul 2025 48.00 (-5.68%) Hold 49.99
Morgan Stanley 11 Jun 2025 40.00 (-21.40%) Hold 57.56
Needham 04 Jun 2025 65.00 (27.73%) Buy 53.61
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BOUGHTON SOLEIL - 58.68 -2,572 -150,925
CHI MICHAEL - 64.37 -26,600 -1,759,481
Aggregate Net Quantity -29,172
Aggregate Net Value ($) -1,910,405
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 62.47
Name Holder Date Type Quantity Price Value ($)
CHI MICHAEL Officer 01 Aug 2025 Automatic sell (-) 250 62.55 15,638
CHI MICHAEL Officer 01 Aug 2025 Option execute 250 - -
CHI MICHAEL Officer 31 Jul 2025 Automatic sell (-) 26,350 66.18 1,743,843
CHI MICHAEL Officer 31 Jul 2025 Option execute 26,350 - -
BOUGHTON SOLEIL Officer 28 Jul 2025 Automatic sell (-) 2,572 58.68 150,925
Date Type Details
07 Aug 2025 Announcement Hims & Hers Health (HIMS) Investors: August 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
05 Aug 2025 Announcement Hims & Hers Health (HIMS) Investors: August 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
04 Aug 2025 Announcement Hims & Hers Health (HIMS) Investors: August 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
04 Aug 2025 Announcement Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results
31 Jul 2025 Announcement Hims & Hers Health (HIMS) Investors: August 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
29 Jul 2025 Announcement Hims & Hers Data Shows Personalized GLP-1 Plans Drive Real Weight Loss, Few Side Effects, and Strong Adherence to Care
29 Jul 2025 Announcement Hims & Hers Health (HIMS) Investors: August 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
14 Jul 2025 Announcement Hims & Hers to Announce Second Quarter 2025 Financial Results on August 4, 2025
09 Jul 2025 Announcement Hims & Hers Announces Planned 2026 Expansion to Canada, Following ZAVA Acquisition Completion
09 Jul 2025 CNBC Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
08 Jul 2025 Announcement INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Hims & Hers Health Inc. to Contact Law Firm
28 Jun 2025 Announcement HIMS INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
23 Jun 2025 CNBC Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%
03 Jun 2025 Announcement Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland
03 Jun 2025 CNBC Hims & Hers to acquire European telehealth platform in global expansion
22 May 2025 Announcement Hims & Hers Introduces 6-Month Wegovy® New Customer Offer
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria